A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCT00926640
Completed
BACKGROUND: * The histone deacetylase (HDAC) inhibitors are a novel class of anticancer agent. These agents lead to the increased acetylation of both histone and non-histone proteins, which leads to rapid cell death in many tumor models. It is thought that the cell death observed with this class of agents may be mediated, in part, through the selective acetylation of histone proteins resulting in increased expression of specific genes. * For solid tumors in general, cell death in preclinical mo... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/18/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms
Register for Updates
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
NCT02254681
Terminated
The overall goal of this study is to determine the safety and efficacy of combination treatment of low-dose fractionated radiation therapy with gemcitabine-cisplatin chemotherapy for locally advanced mass forming intra-hepatic cholangiocarcinoma.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/02/2018
Locations: Virginia Piper Cancer Institute, Minneapolis, Minnesota
Conditions: Intrahepatic Cholangiocarcinoma
Register for Updates
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
NCT00454779
Completed
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically con... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/20/2018
Locations: Research Site, Tucson, Arizona +113 locations
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Register for Updates
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
NCT01752023
Terminated
Response rates. Changes in tumor blood flow.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/18/2018
Locations: Bayview Medical Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Non-small Cell Lung Cancer Metastatic
Register for Updates
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
NCT00064077
Completed
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2018
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Register for Updates
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
NCT02375880
Completed
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
09/06/2018
Locations: University of Southern California, Los Angeles, California +8 locations
Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
Register for Updates
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00002461
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients wit... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
08/15/2018
Locations: Albert Einstein Comprehensive Cancer Center, Bronx, New York
Conditions: Lymphoma
Register for Updates
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01218048
Completed
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed. Thus, the investigators are investigating the role of cellular immunity and immune escape mechanisms to explain the differential clinical response to cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2018
Locations: UPCI - Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
NCT02358863
Terminated
The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2018
Locations: Georgetown University, Washington, District of Columbia
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
NCT00085098
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy alone is as effective as chemotherapy plus radiation therapy in treating germ cell tumor. PURPOSE: This randomized phase III trial is studying radiation therapy alone to see how well it works compared to chemotherapy and radiation therapy in treating patients with... Read More
Gender:
ALL
Ages:
Between 3 years and 25 years
Trial Updated:
08/08/2018
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +106 locations
Conditions: Brain Tumor, Central Nervous System Tumor
Register for Updates
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
NCT00310011
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel and cisplatin works in treating patients with advanced transitional cell cancer of the urothelium.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/08/2018
Locations: Carolinas Hematology-Oncology Associates, Charlotte, North Carolina +2 locations
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Register for Updates
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00003202
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to compare the effectiveness of gemcitabine with radiation therapy alone or following two-drug combination chemotherapy in treating patients with stage III non-small cell lung cancer.
Gender:
ALL
Ages:
120 years and below
Trial Updated:
08/08/2018
Locations: Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina
Conditions: Lung Cancer
Register for Updates